TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519917-72-00

Acronym

ALN-TTRSC04-003

Enrollment

682

Registered

2025-10-14

Start date

2025-10-29

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

Brief summary

Composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits)

Detailed description

•Time to first CV event (CV hospitalizations and urgent HF visits) or all-cause mortality •All-cause mortality •Recurrent CV events •Change from baseline in KCCQ-OS

Interventions

DRUGALN-TTRSC04

DRUGPlacebo for Nucresiran

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits)	—

Secondary

Measure	Time frame
•Time to first CV event (CV hospitalizations and urgent HF visits) or all-cause mortality •All-cause mortality •Recurrent CV events •Change from baseline in KCCQ-OS	—

Countries

Austria, Belgium, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Portugal, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026